Zacks: Brokerages Expect ProNAi Therapeutics, Inc. (SRRA) to Announce -$0.21 Earnings Per Share

Brokerages expect that ProNAi Therapeutics, Inc. (NASDAQ:SRRA) will report earnings of ($0.21) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ProNAi Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.18). ProNAi Therapeutics reported earnings per share of ($0.43) during the same quarter last year, which would suggest a positive year over year growth rate of 51.2%. The firm is scheduled to announce its next earnings results on Friday, August 11th.

According to Zacks, analysts expect that ProNAi Therapeutics will report full-year earnings of ($0.90) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.82). For the next year, analysts expect that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($0.98) to ($0.68). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow ProNAi Therapeutics.

ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.07.

Separately, Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 11th.

ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://baseballnewssource.com/markets/zacks-brokerages-expect-pronai-therapeutics-inc-srra-to-announce-0-21-earnings-per-share-updated/1179668.html.

Several large investors have recently bought and sold shares of SRRA. VHCP Management II LLC bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $200,000. FMR LLC bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $302,000. Greenleaf Trust bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $328,000. Nexthera Capital LP bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $612,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $1,142,000. 60.29% of the stock is currently owned by institutional investors and hedge funds.

ProNAi Therapeutics (NASDAQ SRRA) opened at 1.16 on Wednesday. The stock’s market cap is $60.63 million. ProNAi Therapeutics has a 52 week low of $1.10 and a 52 week high of $2.25. The company’s 50 day moving average is $1.19 and its 200 day moving average is $1.38.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Get a free copy of the Zacks research report on ProNAi Therapeutics (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Chris Sale Reaches 200 Strikeouts in Record Time
Chris Sale Reaches 200 Strikeouts in Record Time
Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.